Document:

<PAGE>
                                                                     EXHIBIT 4.9

                                                                 FORM OF WARRANT

THIS WARRANT AND ANY SECURITIES ACQUIRED UPON THE EXERCISE OF THIS WARRANT HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR
THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR FOREIGN JURISDICTION.
NEITHER THIS WARRANT, SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE
TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH
ACT AND APPLICABLE STATE AND FOREIGN SECURITIES LAWS OR PURSUANT TO AN
APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND SUCH
LAWS.

2003-___

                  ---------------------------------------------

                                 PROXYMED, INC.
                          COMMON STOCK PURCHASE WARRANT

                  ---------------------------------------------

                  This certifies that, for good and valuable consideration,
ProxyMed, Inc., a Florida corporation (the "Company"), grants to
_____________________, a _______ limited partnership (the "Warrantholder"), the
right to subscribe for and purchase from the Company, during the applicable
Exercise Period (as hereinafter defined), up to _______ validly issued, fully
paid and nonassessable shares, par value $0.001, of Common Stock of the Company
(the "Warrant Shares"), in three (3) annual allotments of ______ shares (each an
"Annual Allotment") at the exercise price per share of $16.50, subject to
adjustment pursuant to Section 5 hereof (the "Exercise Price"), all subject to
the terms, conditions and adjustments herein set forth. Capitalized terms used
herein shall have the meanings ascribed to such terms in Section 9 below.

         1. ISSUANCE OF WARRANT; VESTING; DETERMINATION OF INCLUDED REVENUE.

                  1.1 Reserved.

                  1.2 VESTING. The Warrantholder's right to exercise each Annual
Allotment shall become vested and exercisable if, and only if, the following
amounts of Included Revenue (as determined in accordance with Section 1.3) are
achieved during the applicable Measurement Period:

MEASUREMENT PERIOD                 INCLUDED REVENUE     ANNUAL ALLOTMENT
------------------                 ----------------     ----------------

First Measurement Period             $10,000,000         ______ shares

Second Measurement Period            $20,000,000         ______ shares

Third Measurement Period             $30,000,000         ______ shares

Any right of exercise that has vested pursuant to this Section 1.2, but which
has not been exercised on or before the expiration of the applicable Exercise

<PAGE>

Period (as defined in Section 2.1) shall become null and void and of no further
force or effect immediately at such expiration with no further action required
from either party.

                  1.3 DETERMINATION OF INCLUDED REVENUE. As promptly as
practicable, and in any event not later than the fifteenth day after each
Measurement Period, the Company's Chief Financial Officer ("CFO") shall deliver
to the Warrantholder a certificate (the "Annual Certification") setting forth in
reasonable detail the calculation of the amount of Included Revenue for the
applicable Measurement Period and a certification by the CFO that such
calculations are true and correct. The Annual Certification shall be conclusive
evidence of such Included Revenue, unless Warrantholder in good faith objects in
writing to the calculation of Included Revenue set forth in the Annual
Certification no later than five (5) Business Days after its receipt. The
foregoing written objection shall state with specificity any and all of the
grounds on which the Warrantholder objects. The Company and the Warrantholder
shall use their respective reasonable best efforts to resolve any such
objections within five (5) Business Days after the receipt by the Company of
Warrantholders objection. If the Company and the Warrantholder shall fail to
agree on the amount of Included Revenue for a particular Measurement Period
within such five (5) day period, the amount of Included Revenue for such
Measurement Period shall be determined by a certified public accountant ("CPA")
independent of the Company and the Warrantholder, chosen by the Board of
Directors and reasonably acceptable to the Warrantholder. The amount of Included
Revenue determined by the CPA shall be final and binding on each of the Company
and the Warrantholder. The cost of the CPA's certification shall be borne by the
Warrantholder unless the Included Revenue certified by the Company's CFO is
understated by more than five (5) percent, as compared to the Included Revenue
certified by the CPA, in which case the Company shall bear or reimburse the
Warrantholder for the cost of the CPA's certification of Included Revenue. The
Company and the Warrantholder shall cooperate to promptly provide the CPA with
such information as the CPA may reasonably request, and shall use their best
efforts to cause the CPA to complete its certification of Included Revenue
within twenty (20) days after engagement of the CPA.

                  1.4 TERM OF WARRANT. The term of this Warrant shall commence
on the date on which it is executed by the parties and shall expire on the day
after the last day of the Exercise Period following the Third Measurement
Period. The term of this Warrant shall not renew under any circumstances.

        2. EXERCISE OF WARRANT; PAYMENT OF TAXES.

                  2.1 EXERCISE OF WARRANT. Subject to the terms and conditions
set forth herein, provided Warrantholder's right to exercise has vested pursuant
to Section 1.2 of this Warrant, each Annual Allotment may be exercised by the
Warrantholder during the period commencing upon receipt of each Annual
Certification and ending on the later of (X) the sixtieth day following the end
of the preceding Measurement Period or (Y) if the CPA is engaged pursuant to
Section 1.3, the tenth day following the certification of the Included Revenue
by the CPA (the "Exercise Period"), provided that such exercise would not
constitute a Prohibited Exercise, in which case the Exercise Period shall be
extended until the fifth Business Day following the first date upon which such
exercise would not constitute a Prohibited Exercise, by:

                                       2
<PAGE>

                           (a) the delivery to the Company of a duly executed
Exercise Form, and

                           (b) the delivery of payment to the Company, for the
account of the Company, by wire transfer or any other means approved by the
Company, of the aggregate Exercise Price for exercise in lawful money of the
United States of America.

The Company agrees that the Warrant Shares shall be deemed to be issued to the
Warrantholder as the record holder of such Warrant Shares as of the close of
business on the date on which payment is made for the Warrant Shares as
aforesaid. For the avoidance of doubt, cashless exercises of the Warrant shall
not be permitted. Warrantholder shall also surrender this Warrant to the Company
upon the earlier of Warrantholder's permitted exercise in full of the third
Annual Allotment or the termination of this Warrant as per Section 1.4.

                  2.2 WARRANT SHARE CERTIFICATES. A stock certificate or
certificates for the Warrant Shares specified in each Exercise Form shall be
delivered to the Warrantholder within five (5) Business Days after receipt of
both the Exercise Form by the Company and the payment by the Warrantholder of
the aggregate Exercise Price.

                  2.3 PAYMENT OF TAXES. The Company will pay all documentary
stamp or other issuance taxes, if any, attributable to the issuance of Warrant
Shares upon the exercise of this Warrant; PROVIDED, HOWEVER, that the Company
shall not be required to pay any tax or taxes which may be payable in respect of
any transfer involved in the issue or delivery of any Warrants or Warrant
certificates or Warrant Shares in a name other than that of the then
Warrantholder as reflected upon the books of the Company.

         3. RESTRICTIVE LEGEND. Except as otherwise permitted by this Section 3,
each Warrant (and each Warrant issued in substitution for any Warrant pursuant
to Section 6) shall be stamped or otherwise imprinted with a legend in
substantially the form as set forth on the cover of this Warrant.
Notwithstanding the foregoing, the Warrantholder may require the Company to
issue a Warrant or a certificate for Warrant Shares, in each case without a
legend, if either (i) such Warrant or such Warrant Shares, as the case may be,
have been registered for resale under the Securities Act, (ii) the Warrantholder
has delivered to the Company an opinion of legal counsel (from a firm reasonably
satisfactory to the Company) which opinion shall be addressed to the Company and
be reasonably satisfactory in form and substance to the Company's counsel, to
the effect that such registration is not required with respect to such Warrant
or such Warrant Shares, as the case may be or (iii) such Warrant or Warrant
Shares may be sold in accordance with Rule 144 of the Securities Act (or any
successor provision then in effect) under the Securities Act.

         4. RESERVATION AND REGISTRATION OF SHARES. The Company covenants and
agrees as follows:

                           (a) All Warrant Shares that are issued upon the
exercise of this Warrant shall, upon issuance, be validly issued, fully-paid and
nonassessable, and not subject to any preemptive rights, and be free from all
taxes, liens, security interests, charges, and other encumbrances with respect

                                       3
<PAGE>

to the issuance thereof, other than taxes in respect of any transfer occurring
contemporaneously with such issue.

                           (b) The Company shall at all times have authorized
and reserved, and shall keep available and free from preemptive rights, a
sufficient number of shares of Common Stock to provide for the exercise of the
rights represented by this Warrant.

                           (c) The Company shall not, by amendment of its
Articles of Incorporation or through any reorganization, transfer of assets,
spin-off, consolidation, merger, dissolution, issue or sale of securities or any
other action or inaction, seek to avoid the observance or performance of any of
the terms of this Warrant, and shall at all times in good faith assist in
performing and giving effect to the terms hereof.

         5. ANTI-DILUTION ADJUSTMENTS. The Exercise Price and the number of
Warrant Shares to be received upon exercise of this Warrant shall be subject to
adjustment as follows:

                  5.1 DIVIDEND, SUBDIVISION, COMBINATION OR RECLASSIFICATION OF
COMMON STOCK. In the event that the Company shall at any time or from time to
time, after the issuance of this Warrant but prior to the full exercise of all
Annual Allotments, (w) make a dividend or distribution on the outstanding shares
of Common Stock payable in Capital Stock, (x) subdivide the outstanding shares
of Common Stock into a larger number of shares, (y) combine the outstanding
shares of Common Stock into a smaller number of shares or (z) issue any shares
of its Capital Stock in a reclassification of the Common Stock (other than any
such event for which an adjustment is made pursuant to another clause of this
Section 5), then, and in each such case, (A) the aggregate number of Warrant
Shares for which this Warrant is exercisable (the "Warrant Share Number")
immediately prior to such event shall be adjusted (and any other appropriate
actions shall be taken by the Company) so that the Warrantholder shall be
entitled to receive upon exercise of this Warrant the number of shares of Common
Stock or other securities of the Company that it would have owned or would have
been entitled to receive upon or by reason of any of the events described above,
had this Warrant been exercised immediately prior to the occurrence of such
event and (B) the Exercise Price payable upon the exercise of this Warrant shall
be adjusted by multiplying such Exercise Price immediately prior to such
adjustment by a fraction, the numerator of which shall be the number of Warrant
Shares issuable upon the exercise of this Warrant immediately prior to such
adjustment, and the denominator of which shall be the number of Warrant Shares
issuable immediately thereafter. An adjustment made pursuant to this Section 5.1
shall become effective retroactively (x) in the case of any such dividend or
distribution, to a date immediately following the close of business on the
record date for the determination of holders of shares of Common Stock entitled
to receive such dividend or distribution or (y) in the case of any such
subdivision, combination or reclassification, to the close of business on the
day upon which such corporate action becomes effective.

                  5.2 CERTAIN DISTRIBUTIONS. In case the Company shall at any
time or from time to time, after the issuance of this Warrant but prior to the
full exercise of all Annual Allotments, distribute to all holders of shares of
Common Stock (including any such distribution made in connection with a merger
or consolidation in which the Company is the resulting or surviving Person and
shares of Common Stock are not changed or exchanged) cash, evidences of

                                       4
<PAGE>

indebtedness of the Company or another issuer, securities of the Company or
another issuer or other assets (excluding dividends or distributions payable in
shares of Common Stock for which adjustment is made under Section 5.1) or rights
or warrants to subscribe for or purchase any of the foregoing, THEN, and in each
such case, (A) the Exercise Price then in effect shall be adjusted (and any
other appropriate actions shall be taken by the Company) by multiplying the
Exercise Price in effect prior to the date of distribution by a fraction (i) the
numerator of which shall be such Current Market Price of Common Stock
immediately prior to the date of distribution less the then fair market value
(as determined by the Board of Directors in the exercise of their fiduciary
duties) of the portion of the cash, evidences of indebtedness, securities or
other assets so distributed or of such rights or warrants applicable to one
share of Common Stock and (ii) the denominator of which shall be the Current
Market Price of the Common Stock immediately prior to the date of distribution
(but such fraction shall not be greater than one) and (B) the Warrant Share
Number shall be increased by being multiplied by a fraction (i) the numerator of
which shall be the Current Market Price of one share of Common Stock immediately
prior to the record date for the distribution of such cash, evidences of
indebtedness, securities, other assets or rights or warrants and (ii) the
denominator of which shall be the Current Market Price of one share of Common
Stock immediately prior to such record date less the fair market value (as
determined by the Board of Directors in the exercise of their fiduciary duties)
of the portion of such cash, evidences of indebtedness, securities, other assets
or rights or warrants so distributed. Such adjustment shall be made whenever any
such distribution is made and shall become effective retroactively to a date
immediately following the close of business on the record date for the
determination of stockholders entitled to receive such distribution.

                  5.3 OTHER CHANGES. In case the Company at any time or from
time to time, after the issuance of this Warrant but prior to the full exercise
of all Annual Allotments, shall take any action affecting its Common Stock
similar to or having an effect similar to any of the actions described in any of
Sections 5.1, 5.2 or 5.7 (but not including any action described in any such
Section) and the Board of Directors in good faith determines that it would be
equitable in the circumstances to adjust the Exercise Price and Warrant Share
Number as a result of such action, then, and in each such case, the Exercise
Price and Warrant Share Number shall be adjusted in such manner and at such time
as the Board of Directors in good faith determines would be equitable in the
circumstances (such determination to be evidenced in a resolution, a certified
copy of which shall be mailed to the Warrantholder).

                  5.4 NO ADJUSTMENT; PAR VALUE MINIMUM. Notwithstanding anything
herein to the contrary, no adjustment under this Section 5 need be made to the
Exercise Price or Warrant Share Number if the company receives written notice
from the Warrantholder that no such adjustment is required. Notwithstanding any
other provision of this Warrant, the Exercise Price shall not be adjusted below
the par value of a share of Common Stock.

                  5.5 ABANDONMENT. If the Company shall take a record of the
holders of shares of its Common Stock for the purpose of entitling them to
receive a dividend or other distribution, and shall thereafter and before the
distribution to stockholders thereof legally abandon its plan to pay or deliver
such dividend or distribution, then no adjustment in the Exercise Price or
Warrant Share Number shall be required by reason of the taking of such record.

                                       5
<PAGE>

                  5.6 CERTIFICATE AS TO ADJUSTMENTS. Upon any adjustment in the
Exercise Price or Warrant Share Number, the Company shall within a reasonable
period (not to exceed ten (10) days) following any of the foregoing transactions
deliver to the Warrantholder a certificate, signed by (i) the Chief Executive
Officer of the Company and (ii) the Chief Financial Officer of the Company,
setting forth in reasonable detail the event requiring the adjustment and the
method by which such adjustment was calculated and specifying the adjusted
Exercise Price and Warrant Share Number then in effect following such
adjustment.

                  5.7 SPIN-OFF; REORGANIZATION, RECLASSIFICATION, MERGER OR SALE
TRANSACTION.

                           (a) In case of any spin-off by the Company of another
Person (the "Spin-off Entity") at any time after the issuance of this Warrant
but prior to the exercise hereof, the Company shall issue to the Warrantholder a
new warrant, in form and substance satisfactory to the Company and the
Warrantholder, entitling the Warrantholder to purchase, at the exercise price
equal to the excess of the Exercise Price in effect immediately prior to such
spin-off over the adjusted Exercise Price pursuant to Section 5.2, the number of
shares of common stock or other proprietary interest in the Spin-off Entity that
the Warrantholder would have owned had the Warrantholder, immediately prior to
such spin-off, fully exercised any unexpired Annual Allotment under this
Warrant.

                           (b) In case of any capital reorganization,
reclassification, Sale Transaction, merger or consolidation (other than a Sale
Transaction or a merger or consolidation of the Company in which the Company is
the surviving corporation) of the Company or other change of outstanding shares
of Common Stock (other than a change in par value, or from par value to no par
value, or from no par value to par value) (each, a "Transaction") at any time
after the issuance of this Warrant but prior to the exercise hereof, the Company
shall execute and deliver to the Warrantholder at least twenty (20) Business
Days prior to effecting such Transaction a certificate stating that,
notwithstanding the vesting requirements of Section 1.3, each unexpired Annual
Allotment shall be deemed to be vested and exercisable and the Warrantholder
shall have the right thereafter to exercise this Warrant for the kind and amount
of shares of stock or other securities, property or cash receivable upon such
Transaction by a holder of the number of shares of Common Stock into which this
Warrant could have been exercised immediately prior to such Transaction, and
provision shall be made therefor in the agreement, if any, relating to such
Transaction. Such certificate shall provide for adjustments which shall be as
nearly equivalent as may be practicable to the adjustments provided for in this
Section 5. The provisions of this Section 5.7 and any equivalent thereof in any
such certificate similarly shall apply to successive transactions.

                  5.8 NOTICES. In case at any time or from time to time:

                           (a) the Company shall declare a dividend (or any
other distribution) on its shares of Common Stock;

                           (b) the Company shall authorize the granting to the
holders of shares of its Common Stock rights or warrants to subscribe for or
purchase any shares of Capital Stock or any other rights or warrants;

                                       6
<PAGE>

                           (c) there shall occur a spin-off or Transaction; or

                           (d) the Company shall take any other action that
would require a vote of the Company's stockholders;

then the Company shall mail to the Warrantholder, as promptly as possible but in
any event at least ten (10) days prior to the applicable date hereinafter
specified, a notice stating (A) the date on which a record is to be taken for
the purpose of such dividend, distribution or granting of rights or warrants or,
if a record is not to be taken, the date as of which the holders of Common Stock
of record to be entitled to such dividend, distribution or granting of rights or
warrants are to be determined, or (B) the date on which such spin-off or
Transaction is expected to become effective and the date as of which it is
expected that holders of Common Stock of record shall be entitled to exchange
their Common Stock for shares of stock or other securities or property or cash
deliverable upon such spin-off or Transaction. Notwithstanding the foregoing, in
the case of any event to which Section 5.7 is applicable, the Company shall also
deliver the certificate described in such Section 5.7 to the Warrantholder at
least twenty (20) Business Days prior to effecting such reorganization or
reclassification as aforesaid.

         6. LOSS OR DESTRUCTION OF WARRANT. Subject to the terms and conditions
hereof, upon receipt by the Company of evidence reasonably satisfactory to it of
the loss, theft, destruction or mutilation of this Warrant and, in the case of
loss, theft or destruction, of such bond or indemnification as the Company may
reasonably require, and, in the case of such mutilation, upon surrender and
cancellation of this Warrant, the Company will execute and deliver a new Warrant
of like tenor.

         7. OWNERSHIP OF WARRANT. The Company may deem and treat the person in
whose name this Warrant is registered as the holder and owner hereof
(notwithstanding any notations of ownership or writing hereon made by anyone
other than the Company) for all purposes and shall not be affected by any notice
to the contrary, until presentation of this Warrant for registration of
transfer.

         8. AMENDMENTS. Any provision of this Warrant may be amended and the
observance thereof waived only with the written consent of the Company and the
Warrantholder.

         9. DEFINITIONS. As used herein, unless the context otherwise requires,
the following terms have the following respective meanings:

         "AFFILIATE" shall mean any Person who is an "affiliate" as defined in
Rule 12b-2 of the General Rules and Regulations under the Securities Exchange
Act. of 1934, as amended, and the rules and regulations of the Securities and
Exchange Commission thereunder.

         "BOARD OF DIRECTORS" means the Board of Directors of the Company.

         "BUSINESS DAY" means any day other than a Saturday, Sunday or other day
on which commercial banks in the State of New York are authorized or required by
law or executive order to close.

                                       7
<PAGE>

         "CAPITAL STOCK" means, with respect to any Person, any and all shares,
interests, participations, rights in, or other equivalents (however designated
and whether voting or non-voting) of such Person's capital stock and any and all
rights, warrants or options exchangeable for or convertible into such capital
stock (but excluding any debt security whether or not it is exchangeable for or
convertible into such capital stock).

         "COMMERCIAL AGREEMENT" means Master Joint Marketing Agreement dated of
even date herewith between the Company and First Data Resources Inc., as such
agreement may be amended, modified or supplemented from time to time.

         "COMMON STOCK" means the Common Stock, par value $0.001 per share, of
the Company.

         "COMMON STOCK EQUIVALENT" means any security or obligation which is by
its terms convertible into or exercisable into shares of Common Stock,
including, without limitation, any option, warrant or other subscription or
purchase right with respect to Common Stock.

         "COMPANY" has the meaning set forth in the first paragraph of this
Warrant.

         "CURRENT MARKET PRICE" means, as of the date of determination, (a) the
average of the daily Market Price under clause (a), (b) or (c) of the definition
thereof of the Common Stock during the immediately preceding five (5) trading
days ending on such date, and (b) if the Common Stock is not then listed or
admitted to trading on any national securities exchange or quoted in the
over-the-counter market, then the Market Price under clause (d) of the
definition thereof on such date.

         "EXERCISE FORM" means an Exercise Form in the form annexed hereto as
EXHIBIT A.

         "EXERCISE PERIOD" has the meaning set forth in Section 2.1 of this
Warrant.

         "EXERCISE PRICE" has the meaning set forth in the first paragraph of
this Warrant.

         "GOVERNMENTAL AUTHORITY" means the government of any nation, state,
city, locality or other political subdivision thereof, any entity, including,
without limitation, the Nasdaq Stock Market, Inc. and its regulatory arm, the
National Association of Securities Dealers, Inc., exercising executive,
legislative, judicial, regulatory or administrative functions of or pertaining
to government, and any corporation or other entity owned or controlled, through
stock or capital ownership or otherwise, by any of the foregoing.

         "INCLUDED REVENUE" means the combined gross revenue (excluding revenue
related to postage or any other similar costs that are pass-throughs) of the
Company and its subsidiaries (as determined under generally accepted accounting
principles consistently applied) derived from services provided by the Company
to its customers as a result of the Commercial Agreement during the applicable
Measurement Period, without any reduction in such gross revenue for rebates or

                                       8
<PAGE>

other revenue sharing payments paid or payable to First Data Corporation or any
of its Affiliates or to any third party. For the avoidance of doubt, Included
Revenue in a given Measurement Period shall be calculated on a non-cumulative
basis and shall not include any revenue recognized in any other Measurement
Period.

         "MARKET PRICE" means, as of the date of determination, (a) if the
Common Stock is listed on a national securities exchange, the closing price per
share of Common Stock on such date published in THE WALL STREET JOURNAL
(NATIONAL EDITION) or, if no such closing price on such date is published in THE
WALL STREET JOURNAL (NATIONAL EDITION), the average of the closing bid and asked
prices on such date, as officially reported on the principal national securities
exchange on which the Common Stock is then listed or admitted to trading; or (b)
if the Common Stock is not then listed or admitted to trading on any national
securities exchange but is designated as a national market system security by
the National Association of Securities Dealers, Inc., the last trading price of
the Common Stock on such date; or (c) if there shall have been no trading on
such date or if the Common Stock is not designated as a national market system
security by the National Association or Securities Dealers, Inc., the average of
the reported closing bid and asked prices of the Common Stock on such date as
shown by the National Market System of the National Association of Securities
Dealers, Inc. Automated Quotations System and reported by any member firm of the
New York Stock Exchange selected by the Company; or (d) if none of (a), (b) or
(c) is applicable, a market price per share determined mutually by the Board of
Directors and the Warrantholder or, if the Board of Directors and the
Warrantholder shall fail to agree, at the Company's expense by an appraiser
chosen by the Board of Directors and reasonably acceptable to the Warrantholder.
Any determination of the Market Price by an appraiser shall be based on a
valuation of the Company as an entirety without regard to any discount for
minority interests or disparate voting rights among classes of capital stock.

         "MEASUREMENT PERIOD" means the following measurement periods for
measuring Included Revenue: the "First Measurement Period" shall be the period
commencing July 7, 2003 and ending December 31, 2004, inclusive; the "Second
Measurement Period" shall be the period commencing January 1, 2005 and ending
December 31, 2005, inclusive; and the "Third Measurement Period" shall be the
period commencing January 1, 2006 and ending December 31, 2006, inclusive. For
the avoidance of doubt, each Measurement Period is intended to establish the
beginning and ending date for the measurement of Included Revenue, and no excess
Included Revenue from one Measurement Period shall be included in the
calculation of Included Revenue for any other Measurement Period.

         "PERSON" means any individual, firm, corporation, partnership, limited
liability company, trust, incorporated or unincorporated association, joint
venture, joint stock company, governmental body or other entity of any kind.

         "PROHIBITED EXERCISE" means any exercise of this Warrant which would
result in the Warrantholder violating any Requirement of Law, any rule or
regulation of any Governmental Authority, or the Company's Insider Trading
Policy, as modified in good faith by the Company and communicated to the
Warrantholder from time to time.

         "REQUIREMENT OF LAW" means, as to any Person, any law, environmental
law, statute, treaty, rule, regulation, right, privilege, qualification, license
or franchise or determination of an arbitrator or a court or other Governmental
Authority or stock exchange, in each case applicable or binding upon such Person

                                       9
<PAGE>

or any of its property or to which such Person or any of its property is subject
or pertaining to any or all of the transactions contemplated or referred to
herein.

         "SALE TRANSACTION" shall mean (a) (i) the merger or consolidation of
the Company into or with one or more Persons, (ii) the merger or consolidation
of one or more Persons into or with the Company or (iii) a tender offer or other
business combination if, in the case of (i), (ii) or (iii), the stockholders of
the Company prior to such merger or consolidation do not retain at least a
majority of the voting power of the surviving Person or (b) the voluntary sale,
conveyance, exchange or transfer to another Person of (i) the voting Capital
Stock of the Company if, after such sale, conveyance, exchange or transfer, the
stockholders of the Company prior to such sale, conveyance, exchange or transfer
do not retain at least a majority of the voting power of the Company or (ii) all
or substantially all of the assets of the Company.

         "SECURITIES ACT" means the Securities Act of 1933, as amended, and the
rules and regulations of the Securities and Exchange Commission thereunder.

         "SPIN-OFF ENTITY" has the meaning set forth in Section 5.7 of this
Warrant.

         "TRANSACTION" has the meaning set forth in Section 5.7 of this Warrant.

         "WARRANT SHARE NUMBER" has the meaning set forth in Section 5.1 of this
Warrant.

         "WARRANT SHARES" has the meaning set forth in the first paragraph of
this Warrant.

         "WARRANTHOLDER" has the meaning set forth in the first paragraph of
this Warrant.

         10. MISCELLANEOUS.

                  10.1 ENTIRE AGREEMENT. This Warrant constitutes the entire
agreement between the Company and the Warrantholder with respect to the Warrant
and supersedes all prior agreements and understanding with respects to the
subject matter of this Warrant.

                  10.2 BINDING EFFECT; BENEFITS. This Warrant shall inure to the
benefit of and shall be binding upon the Company and the Warrantholder and their
respective permitted successors and assigns. Nothing in this Warrant, expressed
or implied, is intended to or shall confer on any person other than the Company
and the Warrantholder, or their respective permitted successors or assigns, any
rights, remedies, obligations or liabilities under or by reason of this Warrant.

                  10.3 HEADINGS. The headings in this Warrant are for
convenience of reference only and shall not limit or otherwise affect the
meaning of this Warrant.

                  10.4 NOTICES. All notices, demands and other communications
provided for or permitted hereunder shall be made in writing and shall be by
registered or certified first-class mail, return receipt requested, telecopier,
courier service or personal delivery:

                                       10
<PAGE>

              (a)  if to the Company:

                   ProxyMed, Inc.
                   2555 Davie Rd., Suite 110
                   Fort Lauderdale, FL  33317
                   Telecopy:  (954) 473-2341
                   Attention:  Michael K. Hoover, Chief Executive Officer
                                 Rafael G. Rodriguez, Senior Corporate Counsel

                   with a copy to:

                   Holland & Knight LLP
                   701 Brickell Avenue, Suite 3000
                   Miami, FL  33131
                   Telecopy:  (305) 789-7799
                   Attention:  Steven Sonberg, Esq.

              (b)  if to the Warrantholder:

                   c/o General Atlantic Service Corporation
                   3 Pickwick Plaza
                   Greenwich, CT  06830
                   Telecopy:  (203) 618-9207
                   Attention:  Matthew Nimetz

                   with a copy to:

                   Paul, Weiss, Rifkind, Wharton & Garrison LLP
                   1285 Avenue of the Americas
                   New York, NY 10019-6064
                   Telecopy:  (212) 757-3990
                   Attention:  Douglas A. Cifu, Esq.

All such notices, demands and other communications shall be deemed to have been
duly given when delivered by hand, if personally delivered; when delivered by
courier, if delivered by commercial courier service; five (5) Business Days
after being deposited in the mail, postage prepaid, if mailed; and when receipt
is mechanically acknowledged, if telecopied. Any party may by notice given in
accordance with this Section 10.4 designate another address or Person for
receipt of notices hereunder.

                  10.5 SEVERABILITY. Any term or provision of this Warrant which
is invalid or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such invalidity or unenforceability without
rendering invalid or unenforceable the terms and provisions of this Warrant or
affecting the validity or enforceability of any of the terms or provisions of
this Warrant in any other jurisdiction.

                                       11
<PAGE>

                  10.6 GOVERNING LAW. THIS WARRANT SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF FLORIDA WITHOUT REGARD TO
THE CONFLICTS OF LAW PRINCIPLES THEREOF.

                  10.7 NO RIGHTS OR LIABILITIES AS STOCKHOLDERS. Nothing
contained in this Warrant shall be determined as conferring upon the
Warrantholder any rights as a stockholder of the Company or as imposing any
liabilities on the Warrantholder to purchase any securities whether such
liabilities are asserted by the Company or by creditors or stockholders of the
Company or otherwise.

                [Remainder of this page intentionally left blank]

                                       12
<PAGE>

                  IN WITNESS WHEREOF, the Company has caused this Warrant to be
signed by its duly authorized officer.

                                      PROXYMED, INC.

                                      By: /s/ JUDSON E. SCHMID
                                          -------------------------------------
                                           Name:  Judson E. Schmid
                                           Title: EVP & Chief Financial Officer

Dated: July 8, 2003

                                       13
<PAGE>

                                    EXHIBIT A

                                  EXERCISE FORM

                 (To be executed upon exercise of this Warrant)

                  The undersigned hereby irrevocably elects to exercise the
right, represented by this Warrant, to purchase [________] shares of Common
Stock and herewith tenders payment for such shares to the order of the Company
in the amount of $[______] in accordance with the terms of this Warrant. The
undersigned requests that a certificate for such Warrant Shares be registered in
the name of the undersigned and that such certificates be delivered to the
undersigned's address below.

                  The undersigned represents that it is acquiring such shares
for its own account for investment and not with a view to or for sale in
connection with any distribution thereof (subject, however, to any requirement
of law that the disposition thereof shall at all times be within its control).

Dated:

                                            -----------------------------------
                                            Signature

                                            -----------------------------------
                                            (Print Name)

                                            -----------------------------------
                                            (Street Address)

                                            -----------------------------------
                                            (City)      (State)     (Zip Code)<PAGE>
                                                                    EXHIBIT 10.1

                              EMPLOYMENT AGREEMENT

         THIS EMPLOYMENT AGREEMENT ("Agreement") is made and entered on May 13,
2003 by and between ProxyMed, Inc., a Florida corporation (the "Company"), and
Thomas Wohlford ("Associate").

         WHEREAS, upon the terms and subject to the conditions of this
Agreement, the Company desires to employ the Associate, and Associate is willing
to accept such employment.

         NOW, THEREFORE, in consideration of the mutual covenants and agreements
set forth hereinafter and other good and valuable considerations, the receipt
and sufficiency of which are hereby acknowledged, the Company and the Associate
intending to be legally bound agree as follows:

         1. TERM. The initial term of the Agreement shall commence on May 13,
2003 (the "Effective Date"), and shall continue for three (3) years and shall be
automatically renewed from year to year thereafter (hereafter, the initial term
and any renewals thereof shall constitute the "Term"), unless either party
provides the other party with notice of its intent not to renew this Agreement
not less than ninety (90) days nor more than 120 days prior to the expiration of
the then-current term or unless this Agreement is earlier terminated in
accordance with its terms.

         2. POSITION; DUTIES; LOYALTY.

                  a) POSITION. Associate will be employed by Company and shall
render service to Company as its Vice President of Operations, reporting to the
Lonnie Hardin, Senior Vice President - Payer Services of ProxyMed, or his
designees, pursuant to the terms, provisions and conditions hereinafter set
forth.

                  b) DUTIES. Associate shall be employed by Company on a
full-time, exclusive basis and will not be required to relocate as a condition
of continued employment. Associate will be required to travel on business, as is
customary and usual for Associate's position. Associate shall perform such
duties and have such authority and responsibilities customarily accompanying
his/her position and as reasonably directed by the Lonnie Hardin, Senior Vice
President - Payer Services of ProxyMed, or his designees of the Company
consistent with the Associate's position. Associate shall perform the duties and
have the authority and responsibilities customarily accompanying those of a Vice
President of a public company, including without limitations, those prescribed
by the Company's By-laws or as may be assigned to the Associate from time to
time by the Company's Board of Directors.

                  c) LOYALTY. Associate shall devote the full working time
required for Associate's position and shall give Associate's best efforts to the
business of the Company and to the performance of the duties and obligations
described in this Agreement. Except as maybe authorized in writing by the CEO of
the Company, Associate shall not, directly or indirectly, alone, or as a
partner, officer, director or shareholder of any other institution, be engaged
in any other commercial activities whatsoever, or continue or assume any other
corporate affiliations except for (i) an Affiliate; (ii) passive investments;
and (iii) minimal time utilized for business activities that do not compete with
the business of the Company or its subsidiaries. As used herein, the term
"Affiliate" shall refer to any entity that is owned or controlled by, under
common ownership or control with, or which owns or controls the Company or any
of its subsidiaries, now or in the future.

         3. COMPENSATION AND EXPENSES.

                  a) SALARY. In consideration for the services rendered by the
Associate under this Agreement, Company shall pay the Associate a monthly base

<PAGE>

salary of $14,583.33 per month ("Base Salary") in accordance with the Company's
customary payroll practices. Associate performance reviews (with or without a
wage increase) will be conducted at least annually or as otherwise agreed to by
the parties in writing. The Company shall adjust associate's Base Salary for any
wage increases approved in writing by the Board of Directors or its Compensation
Committee in its sole discretion. As used herein, the term "Base Compensation"
shall refer collectively to (i) Associate's Base Salary, adjusted for any wage
increases, (ii) the Options (as defined in Section 3(b)), (iii) future options
granted pursuant to any Stock Option Plans (as defined in Section 3(b)), (iv)
any Bonuses, (v) any bonuses to which Associate may be entitled pursuant to any
Bonus Plan, (vi) Vacation; and (vii) Benefits.

                  b) BONUS AND STOCK OPTIONS. Associate will receive an initial
stock option agreement, incorporated herein by reference, which shall have a ten
(10) year term, and which shall allow Associate to purchase up to 10,000 shares
of ProxyMed common stock (the "Stock Options") at its fair market value defined
as the price at which common stock is reported to have traded on the NASDAQ
System at the close of business on the Effective Date. The options will vest
over a three (3) year period as follows: 1/3 on the first anniversary of the
Effective Date, 1/3 on the second anniversary of the Effective Date, and 1/3 on
the day before the third anniversary of the Effective Date. The Stock Options
granted hereunder shall be governed exclusively by and issued in accordance with
the terms of the Company's 2002 Stock Option Plan, incorporated herein by
reference. As a further incentive and inducement to the Associate to commence
and continue his employment with the Company and to devote his best efforts to
the business and affairs of the Company, the Associate shall be entitled to and
may earn such bonuses ("Bonuses") as may be awarded from time to time by the
Board of Directors of the Company, sitting as a whole or in committee, in its
sole discretion, including pursuant to any bonus plan ("Bonus Plan") implemented
by the Company, and to participate in any stock option plans ("Stock Option
Plans") or other Bonus Plans which the Company may now have or in the future
develop and for which the Associate qualifies for eligibility under the terms of
such plan.

                  c) EXPENSES. Company shall promptly pay or reimburse the
Associate for all reasonable business expenses actually incurred or paid by the
Associate in the performance of Associate's services hereunder in accordance
with the policies and procedures of the Company, provided that Associate
properly accounts therefor.

                  d) TAX WITHHOLDING. The Company shall have the right to deduct
or withhold from all compensation due Associate hereunder any and all sums
required, including without limitation for Federal income, social security and
Medicare taxes and all state and local taxes now applicable or that may be
enacted and become applicable in the future.

                  e) TIME IN SERVICE. The Company will recognize Associate's
time in service as January 2, 2002 as it relates to all benefits, stock option
vesting rights and other such benefits where time in service is a determinative
factor.

         4. BENEFITS.

                  a) VACATION. The Associate shall be entitled to a yearly
vacation of three (3) weeks during the first year of this Agreement, and
thereafter such additional time as may be provided by the Company in writing in
its then-current policies or otherwise, at full pay to be accrued and taken in
accordance with the Company's policies in effect from to time ("Vacation").
Vacation shall accrue ratably during each calendar year in accordance with
Company policies. Vacation not taken in one calendar year may be carried over to
the following calendar year subject to any limitations set forth in the Company
policies in effect from time to time. Associate shall not be entitled to receive
any additional compensation from the Company for Associate's failure to take all
of Associate's granted vacation time. In the event Associate's employment is
terminated pursuant to Section 5(b) below, any vacation time used but not earned
at the time of termination shall be deducted from any monies owed to Associate.

                                       2
<PAGE>

                  b) PARTICIPATION IN BENEFIT PLANS. Associate shall be eligible
for and entitled to receive all other benefits and perquisites ("Benefits")
offered or extended to other Vice Presidents of the Company.

                  c) CHANGES IN FORM OF EMPLOYMENT AGREEMENT. If the
Compensation Committee of ProxyMed's Board of Directors amends the form of
employment agreement to be used for vice presidents of the company, as approved
by them on March 28, 2003, then this agreement shall be likewise amended.

         5. TERMINATION.

                  a) INVOLUNTARY TERMINATION FOR DEATH OR DISABILITY. This
Agreement shall terminate immediately upon Associate's death. The Company may
terminate Associate's employment with the Company for Disability. For purposes
of this Agreement, "Disability" is defined to mean the inability of Associate
due to illness or physical or mental infirmity (as determined by a physician
selected by Associate and acceptable to the Company) to perform Associate's
duties hereunder on a full-time basis for six (6) consecutive months with
reasonable accommodation by the Company. Upon termination due to death or
Disability, Associate or Associate's beneficiary or estate or legal
representative shall be entitled to receive the amounts payable under Section
5(c).

                  b) TERMINATION BY COMPANY FOR CAUSE. The Company may terminate
Associate's employment with the Company at any time "For Cause" effective
immediately, unless stated otherwise in writing, upon giving written notice
thereof to Associate, which notice shall state with reasonable specificity the
facts supporting the termination "For Cause." "For Cause" shall include the
following:

                           (i) Conviction of, or pleading guilty to, a felony or
any crime involving moral turpitude, fraud, dishonesty or theft or engaging in
any act which is a violation of any law or regulation protecting the rights of
employees or

                           (ii) Failure by Associate to satisfactorily perform
the duties stated herein or to substantially perform such duties in accordance
with any tasks, goals, and objectives as assigned from time to time by the
Company in writing, if Associate has not corrected or remedied, or has not
commenced to correct or remedy, such unsatisfactorily or non-substantial
performance of such specified duties within thirty (30) days (or such other time
as may be provided in writing by the Company) of Associate's actual receipt of
such written notice; or

                           (iii) Associate's gross negligence or willful
misconduct relating to the Company that is materially injurious to the Company;
or

                           (iv) Associate's excessive use of alcohol or illegal
drugs that (A) interferes with the performance of Associate's duties hereunder
and (B) continues even after written warning regarding such excessive use is
actually received by Associate; or

                           (v) Associate's abandonment of his position or
termination of this Agreement for "No Good Reason;" or

                           (vi) Any material breach by Associate of this
Agreement or of any of the Company's applicable written policies then in effect,
including without limitations, the Company's Code of Ethics for Officers and
Directors with written notice thereof by the Company, provided such notice is
actually received by Associate and an appropriate period to cure such material
breach, if such breach is curable, is given and has expired.

                                       3
<PAGE>

                  Upon the Company's termination of this Agreement and
Associate's employment For Cause, the Associate shall be entitled to, and the
Company shall pay the Associate the following "For Cause Separation Pay": the
Associate's Base Salary and benefits through the effective date of termination
at the Associate's then current rate (including any applicable pro rated bonus
and accrued vacation pay). Except as provided for herein or in any other written
agreement, the Company shall have no other liabilities or obligations to
Associate upon payment in full of the For Cause Separation Pay.

                  c) TERMINATION BY COMPANY WITHOUT CAUSE. The Company may
terminate "Without Cause" Associate's employment with the Company or this
Agreement at any time for any or no reason by giving the Associate thirty (30)
days prior written notice to the termination date. Such termination by Company
shall be deemed to be "without cause" by the Company. In the event of
termination by the Company pursuant to this Section, Associate shall execute a
full and complete release of any and all claims against the Company in a form
satisfactory to the Company, in which event, for a period of three (3) months
commencing from the effective date of termination, the Associate shall be
entitled to and shall receive, and the Company shall pay the following "Without
Cause Separation Pay": (i) An amount equal to Associate's Base Salary as of the
date of termination; plus (ii) a pro rata portion of any accrued vacation not
already taken and of any bonus that would have been paid to Associate under any
bonus plan which is adopted by the Company's Compensation Committee or Board of
Directors in such year if the Company and Associate had met the targeted goals
to the date of termination; plus (iii) the continuation for three (3) months
from the effective date of termination of all of Associate's benefits including,
without limitation, all insurance plans, on the same terms and conditions as had
been provided to Associate prior to the termination, all of the foregoing which
shall be payable in accordance with the Company's customary payroll practices
then in effect; plus (iv) the immediate vesting of all granted options that have
not already expired.

                  d) TERMINATION BY ASSOCIATE FOR GOOD REASON. Associate may
terminate this Agreement for "Good Reason" by giving the Company thirty (30)
days prior written notice (the "Notice Period)] to that effect, specifically
stating Associate's Good Reason for terminating in sufficient detail to allow
the Company to respond effectively to the notice, with the termination becoming
effective on the 31st day after such notice is actually received by the Company
(the "Termination Date"), unless the Company at its option cures any alleged
breach, if curable, on or before the Termination Date, or if the breach is not
capable of being cured within the Notice Period, Company made good faith efforts
to cure any alleged breach prior to the Termination Date. The stated Good Reason
must be one or more of any of the reasons defined as a "Good Reason" herein. As
used in this Agreement, a "Good Reason" means termination by Associate only for
any one or more of the following reasons:

                           (i) Any reduction of Associate's then-current Base
Salary without Associate's prior written consent; or

                           (ii) Any material breach of this Agreement by the
Company, not cured or in the process of being cured by the Company as provided
herein after the Company receives not less than 30 days prior written notice by
the Associate.

                  An Associate's termination for any of the foregoing Good
Reasons shall be treated the same as a termination "Without Cause" by the
Company for purposes of calculating separation pay, entitling the Associate to
the Without Cause Separation Pay set forth in Section 5(c).

                  e) TERMINATION BY ASSOCIATE FOR NO GOOD REASON. Associate may
terminate this Agreement for any reason (other than a Good Reason) or no reason
at any time with not less than thirty (30) days prior written notice to the
Company (such termination shall be called a termination for "No Good Reason").
After the Company receives notice of a termination for No Good Reason, the
Company may by written notice to the Associate cause the effective date of any
such termination to be accelerated without causing such termination to be

                                       4
<PAGE>

considered a termination by the Company Without Cause. Associate's termination
for No Good Reason shall be treated the same as a termination "For Cause" by the
Company for purposes of calculating separation pay, entitling the Associate to
the For Cause Separation Pay set forth in Section 5(b). For avoidance of doubt,
a termination by Associate for any reason that is also a Good Reason shall be
treated as a termination by Associate for Good Reason as set forth in Section
5(d).

                  f) RETURN OF COMPANY PROPERTY. Upon any termination of this
Agreement, Associate shall immediately return to the Company all property of the
Company in Associate's possession, including Confidential Information (as
defined below). Associate acknowledges that the Company may withhold any
compensation and benefits owed to Associate hereunder until all such property is
returned in good condition, normal wear and tear excepted.

                  g) CHANGE IN CONTROL. If, within ninety (90) days prior to a
Change of Control, as defined in Associate's Stock Option Agreement, the
Agreement terminates for any reason (other than pursuant to Section 5(b) or (e)
above), then, (i) any unvested options shall vest as of the date of the Change
of Control and shall remain vested and exercisable as specified in Associate's
Stock Option Agreement, and (ii) Associate shall receive, and the Company shall
pay the Associate, the "Without Cause Separation Pay" set forth in Section 5(c)
above.

         6. COVENANTS OF ASSOCIATE.

                  a) Associate agrees that during the Term of this Agreement and
for one (1) year following its expiration or termination for any or no reason,
including without limitation, "For Cause", "Without Cause", "For Good Reason",
or "No Good Reason", Associate will not, directly or indirectly, without the
prior written consent of the Company, induce or solicit any person employed or
hereafter employed by the Company to leave the employ of the Company, or
solicit, recruit, hire or attempt to solicit, recruit or hire any person
employed by the Company.

                  b) Associate agrees that for a period of two (2) years after
the expiration or termination of this Agreement for any or no reason, including
without limitation, "For Cause", "Without Cause", "For Good Reason", or "No Good
Reason", Associate will not, directly or indirectly, without the prior written
consent of the Company, solicit or attempt to solicit, divert or take away, or
attempt to divert or take away, Customers or their laboratory business from the
Company and/or the Company's then-current Affiliates. As used in the preceding
sentence, the term "Customer" shall include, however known to Associate as of
the date of such termination or expiration, (i) any current end-user of the
Company's or its then-current Affiliates' products or services, or any potential
end-user thereof with whom the Company or its then-current Affiliates have had
contact with within the preceding six (6) months; (ii) any current suppliers of
the Company's or its then-current Affiliates; and/or (iii) vendor of the Company
or its then-current Affiliates or reseller of the Company or its then-current
Affiliates; and/or (iv) their Affiliates, successors or assigns. The foregoing
notwithstanding for purposes of this covenant the term "Customer" shall not
include those customers previously known to Affiliate and listed on Exhibit "A"
hereto, which is hereby incorporated by reference, as mutually amended by the
parties from time to time.

                  c) Associate agrees and acknowledges that Associate will
disclose promptly to the Company every discovery, improvement and invention
made, conceived or developed by Associate during the entire period of employment
(whether or not during working hours) which discoveries, improvements or
inventions are capable of use in any way in connection with the business of the
Company. To the fullest extent permitted by law, all such discoveries,
inventions and improvements will be deemed works made-for-hire. Associate grants
and agrees to convey to Company or its nominee the entire right, title and
interest, domestic and foreign, which Associate may have in such discoveries,
improvements or inventions, or a lesser interest therein, at the option of
Company. Associate further agrees to promptly, upon request, sign all

                                       5
<PAGE>

applications for patents, copyrights, assignments and other appropriate
documents, and to perform all acts and to do all things necessary and
appropriate to carry out the intent of this section, whether or not Associate is
still an employee of the Company at the time of such requests.

                  d) Associate agrees and acknowledges that the Confidential
Information of the Company is valuable, special and unique to its business, that
such business depends on such Confidential Information, and that the Company
wishes to protect such Confidential Information by keeping it confidential for
the exclusive use and benefit of the Company. Based on the foregoing, Associate
agrees to undertake the following obligations with respect to such Confidential
Information:

                           (i) Associate agrees to keep any and all Confidential
Information in trust for the use and benefit of the Company;

                           (ii) Associate agrees that, except as required by
Associate's duties or authorized in writing by the Company, Associate will not
at any time during and for a period of three (3) years after the termination of
Associate's employment with the Company, disclose, directly or indirectly, any
Confidential Information of the Company to any third party; except as may be
required by applicable law or court order, in which case Associate shall
promptly notify Company so as to allow it to seek a protective order if it so
elects;

                           (iii) Associate agrees to take all reasonable steps
necessary, or reasonably requested by the Company, to ensure that all
Confidential Information of the Company is kept confidential for the use and
benefit of the Company and its subsidiaries; and

                           (iv) Associate agrees that, upon termination of
Associate's employment by the Company or at any other time the Company may in
writing so request, Associate will promptly deliver to the Company all materials
constituting Confidential Information (including all copies and derivatives
thereof) that are in the possession of or under the control of Associate.
Associate further agrees that, if requested by the Company to return any
Confidential Information pursuant to this Subsection (iv), Associate will not
make or retain any copy or extract from such materials.

     For the purposes of this Section 6(d), "Confidential Information" means any
and all information, including derivative works, developed by or for the Company
or entrusted to the Company in confidence by its customers, of which Associate
gained knowledge by reason of Associate's employment by the Company, which is
not generally known in any industry in which the Company is or may become
engaged, but does not apply to information which is generally known to the
public or the trade, unless such knowledge results from an unauthorized
disclosure by Associate. Confidential Information includes, but is not limited
to, any and all information developed by or for the Company concerning plans,
marketing and sales methods, materials, processes, business forms, procedures,
devices used by the Company, its suppliers and customers with which the Company
had dealt with prior to Associate's termination of employment with the Company,
plans for development of new products, services and expansion into new areas or
markets, internal operations, and any trade secrets, proprietary information of
any type owned by the Company, together with all written, graphic and other
materials relating to all or any part of the same. The Company will receive all
materials, including, software programs, source code, object code,
specifications, documents, abstracts and summaries developed in connection with
Associate's employment. Associate acknowledges that the programs and
documentation developed in connection with Associate's employment with the
Company shall be the exclusive property of the Company, and that the Company
shall retain all right, title and interest in such materials, including without
limitation patent and copyright interests. Nothing herein shall be construed as
a license from the Company to Associate to make, use, sell or copy any
inventions, ideas, trade secrets, trademarks, copyrightable works or other
intellectual property of the Company during the Term of this Agreement or
subsequent to its termination.

                                       6
<PAGE>

                  e) Associate acknowledges that there is no general
geographical restriction contained in this Section 6(d) because the Company's
and/or Affiliates' Customers are not confined to one geographical area or
operate on a national level. Notwithstanding the foregoing, if a court of
competent jurisdiction were to determine that any of the foregoing covenants
would be held to be unreasonable in time or distance or scope, the time or
distance or scope may be reduced by appropriate order of the court to that
deemed reasonable.

                  f) Associate confirms that Associate is not bound by the terms
of any agreement with any previous Company or other party which restricts in any
way Associate's use or disclosure of information or Associate's engagement in
any business, except as Associate may disclose in a separate schedule attached
to this Agreement prior to Company's and Associate's execution of this
Agreement. Further, Associate represents that Associate has delivered to the
Company prior to executing this Agreement true and complete copies of any
agreements disclosed on such attached schedule. Associate represents to the
Company that Associate's execution of this Agreement, employment with the
Company and the performance of Associate's proposed duties for the Company will
not violate any obligations Associate may have to any such previous Company or
other party. In any work for the Company, Associate will not disclose or make
use of any information in violation of any agreements with or rights of any such
previous Company or other party, and will not bring to the premises of the
Company any copies or other tangible embodiments of non-public information
belonging to or obtained from any such previous employment or other party. In
the event of breach of this subsection (f) Associate hereby agrees to defend,
indemnify and hold harmless ProxyMed, its officers, directors, employees, agents
(the "Indemnified Parties") from any and all damages, suits, claims,
liabilities, actions (individually and collectively, the "Indemnity Event")
arising or resulting from such breach. In the event of any Indemnity Event, the
Indemnified Parties shall provide Associate with timely written notice of same,
and thereafter Associate shall at its own expense defend, protect and hold
harmless the applicable Indemnified Parties against said Indemnity Event. If the
Associate shall fail to so defend and/or indemnify and save harmless the
Indemnified Parties, then in such instance the Indemnified Parties shall have
full rights to defend, pay or settle said Indemnity Event on their behalf
without notice to Associate and with full rights to recourse against Associate
for all fees, costs, expenses and payments made or agreed to be paid to
discharge said Indemnity Event.

                  g) ASSISTANCE IN LITIGATION. Associate shall upon reasonable
notice, furnish such information and proper assistance to the Company as it may
reasonably require in connection with any litigation in which the Company is, or
may become, a party either during or after Associate's employment with the
Company.

                  h) INJUNCTIVE RELIEF.

                           i) Associate acknowledges and agrees that the
covenants and obligations contained in this Section 6 relate to special, unique
and extraordinary matters and that a violation of any of the terms of this
Section will cause the Company irreparable injury for which adequate remedies at
law are not available. Therefore, Associate agrees that the Company shall be
entitled (without having to post a bond or other surety) to an injunction,
restraining order, or other equitable relief from any court of competent
jurisdiction, restraining the Associate from committing any violation of the
covenants and obligations set forth in this Section 6.

                           ii) The Company's rights and remedies under this
Section 6 are cumulative and are in addition to any other rights and remedies
the Company may have pursuant to the specific provisions of this Agreement and
at law or in equity.

                                       7
<PAGE>

         7. MISCELLANEOUS.

                  a) ATTORNEY'S FEES. In the event a proceeding is brought to
enforce or interpret any part of this Agreement or the rights or obligations of
any party to this Agreement, each party shall pay their own fees and expenses,
including reasonable attorney's fees and costs

                  b) SUCCESSORS AND ASSIGNS. This Agreement and the benefits
hereunder are personal to the Company and are not assignable or transferable by
the Associate. Subject to the foregoing, this Agreement shall be binding upon
and inure to the benefit of the Company and the Associate, and the Associate's
heirs and legal representatives, and the Company's successors and assigns.

                  c) GOVERNING LAW. This Agreement shall be construed in
accordance with and governed by the law of the State of Georgia.

                  d) ARBITRATION. Except for disputes relating to Section 6(d)
of this Agreement or any injunctions, any and all disputes or controversies that
shall arise under or in connection with this Agreement or in any other way
related to Associate's employment by the Company, including termination of
employment, shall be submitted to a panel of three arbitrators under the
National Rules for the Resolution of Employment Disputes of the American
Arbitration Association then in effect. The parties hereby acknowledge that the
Federal Arbitration Act takes precedence over any state arbitration statutes,
rules and regulations. Each of the arbitrators shall be qualified and
experienced in employment related matters with at least one arbitrator being a
licensed attorney. The arbitrators must base their determination solely on the
terms and conditions of this Agreement and the law in the State of Georgia. The
arbitrators shall have the authority to award any remedies that a court may
order or grant, except that they will have no authority to award punitive
damages or any other damages not measured by the prevailing party's actual
damages, and may not, in any event, make any ruling, finding or award that does
not conform to the terms and conditions of this Agreement. Arbitration shall be
held either in Atlanta, Georgia, and the parties hereby agree to accept service
of process served in accordance with the Notices provision of this Agreement and
in the personal jurisdiction and venue as set out herein. Both parties expressly
covenant and agree to be bound by the decision of the arbitrators as the final
determination of the matter in dispute. Judgment upon the award rendered by the
arbitrators may be entered into any court having jurisdiction thereof.

                  e) NOTICES. All notices and other communications required or
permitted to be given under this Agreement shall be in writing and shall be
deemed to have been given if delivered personally or sent by certified mail,
return receipt requested, postage prepaid, to the parties to this Agreement
addressed to the Company's then-current CEO at its then principal office, as
notified to Associate, or to the Associate at Associate's most current address
as shown in Associate's personnel file, or to either party hereto at such other
address or addresses as Associate or it may from time to time specify for such
purposes in a notice similarly given.

                  f) MODIFICATION; WAIVER. No provisions of this Agreement may
be modified, waived or discharged unless such modification, waiver or discharge
is approved by a duly authorized officer of the Company and is agreed to in a
writing signed by the Associate and such officer. No waiver by either party
hereto at any time of any breach by the other party hereto of, or compliance
with, any condition or provision of this Agreement to be performed by such other
party shall be deemed a waiver of similar or dissimilar provisions or conditions
at the same or at any prior or subsequent time.

                  g) HEADINGS. The headings in this Agreement are for
convenience of reference only and shall not control or affect the meaning or
construction of this Agreement.

                                       8
<PAGE>

                  h) VALIDITY. The invalidity or unenforceability of any one or
more provisions of this Agreement shall not affect the validity or
enforceability of any other provision of this Agreement, which shall remain in
full force and effect.

                  i) SEVERABILITY. The invalidity of any one or more of the
words, phrases, sentences, clauses or sections contained in this Agreement shall
not affect the enforceability of the remaining portions of this Agreement or any
part thereof, all of which are inserted conditionally on their being valid in
law, and if any one or more of the words, phrases, sentences, clauses or
sections contained in this Agreement shall be declared invalid, this Agreement
shall be construed as if such invalid word or words, phrase or phrases, sentence
or sentences, clause or clauses, or section or sections had not been inserted.

                  j) COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall be deemed to be an original but all of which
together will constitute one and the same instrument.

                  k) SURVIVING PROVISIONS. Any portion of this Agreement which
by it nature survives the termination of this Agreement, including Section 6,
shall survive the termination of this Agreement.

                  l) ENTIRE AGREEMENT. Except as modified by this Agreement, all
of Associate's benefits and obligations are as set forth in the Company's
policies in effect from time to time. Other than the Company's policies in
effect from time to time, as modified herein, no agreements or representations,
oral or otherwise, express or implied, with respect to the subject matter hereof
have been made by either party, which are not set forth expressly in this
Agreement. This Agreement constitute the final and entire agreement between the
parties, and supercedes all prior written and oral agreements, understandings,
or communications with respect to the subject matter of this Agreement.

                  IN WITNESS WHEREOF, the parties have executed this Agreement
as of the date and year first above written.

PROXYMED, INC.                        ASSOCIATE

By:        /s/ NANCY J. HAM           By:        /s/ THOMAS C. WOHLFORD, III
      ---------------------------           --------------------------------
      SIGNATURE                                  SIGNATURE

Print Name:     NANCY J. HAM          Print Name:     THOMAS C. WOHLFORD, III
             --------------------                ----------------------------

                                       9
<PAGE>

                                   EXHIBIT "A"

                 (TO BE PROVIDED BY ASSOCIATE IN WRITING TO THE
                  COMPANY'S SR. CORPORATE COUNSEL WITHIN NINETY
                   (90) DAYS OF EXECUTION OF THIS AGREEMENT.)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}]]